Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 6/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ROS1 | P08922 | 1/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461050 | 0.87 | FLT3 (0.44) | FLT3PIK3CASMN1; SMN2EPHB3IRAK4 | |
| SCHEMBL401639 | 0.85 | FLT3 (0.41) | FLT3PIK3CANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL448581 | 0.84 | TGFBR1 (0.46) | FLT3IRAK4TYK2JAK2NTRK1 | |
| SCHEMBL10190991 | 0.83 | PDE4B (0.47) | FLT3NPC1RAB9AEPHB3IRAK4 | |
| SCHEMBL30993352 | 0.83 | TGFBR1 (0.49) | NPC1RAB9ASMN1; SMN2EPHB3NLRP3 | |
| SCHEMBL4102470 | 0.82 | TYK2 (0.38) | NPC1RAB9ASMN1; SMN2IRAK4TYK2 | |
| SCHEMBL4106502 | 0.82 | TYK2 (0.52) | NPC1RAB9ASMN1; SMN2IRAK4TYK2 | |
| SCHEMBL22097418 | 0.82 | FLT3 (0.38) | FLT3PIK3CANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30267077 | 0.80 | FLT3 (0.38) | FLT3PIK3CAEPHB3JAK2NTRK1 | |
| SCHEMBL402097 | 0.80 | JAK2 (0.48) | IRAK4JAK2NTRK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166156-B | Tyrosine kinase inhibitors, compositions and methods | 贝达药业股份有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230250110-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11685750-B2 | Crystalline forms of IRAK degraders | KYMERA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20210395256-A1 | TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| CN-113166156-A | Tyrosine kinase inhibitors, compositions and methods thereof | 贝达药业股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020233645-A1 | MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | 浙江海正药业股份有限公司 (CN) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020114499-A1 | TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-06-11 | — | — | WO | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395256-A1 | TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF | ABL1, LCK, ERBB2 | FLT3 43/4885PIK3CA 110/4885NPC1 1809/4885 |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | FLT3 60/4885PIK3CA 142/4885NPC1 3159/4885 |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | FLT3 16/4885PIK3CA 255/4885NPC1 2785/4885 |
| US-11685750-B2 | Crystalline forms of IRAK degraders | IRAK1, IRAK2, IRAK4 | FLT3 383/4885PIK3CA 1122/4885NPC1 973/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | FLT3 60/4885PIK3CA 142/4885NPC1 3159/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | FLT3 60/4885PIK3CA 142/4885NPC1 3159/4885 |
| US-20230250110-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | FLT3 39/4885PIK3CA 293/4885NPC1 3929/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | FLT3 60/4885PIK3CA 142/4885NPC1 3159/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | FLT3 60/4885PIK3CA 142/4885NPC1 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.